Aryan Chauhan Zivov is drawing attention in India’s healthtech space as diabetes care faces rising costs and limited access. At 22, Aryan Chauhan is the co-founder of Zivov, a Gurugram-based startup that uses technology to support diabetes remission and glucose tracking. While many at his age are finishing college, Aryan Chauhan is on academic leave from the University of Pennsylvania to build his second startup.

Aryan Chauhan studies in the Jerome Fisher Program in Management and Technology at the University of Pennsylvania. The program admits fewer than five percent of applicants. Chauhan has one semester left but chose to pause his studies to focus on Zivov’s growth.

Early start in startups

Aryan Chauhan began building companies at a young age. At 14, he started Bizchirp, a platform that helped startups and small firms connect and work together. The project gave him early exposure to product design, user needs, and day-to-day operations.

After school, Chauhan earned a place at the University of Pennsylvania. During his studies, he stayed close to startup work and early-stage investing. When the Covid-19 pandemic began in 2020, he returned to India. Instead of slowing down, he used the time to learn how Indian startups operate on the ground.

Learning from venture investing

During this period, Aryan Chauhan reached out to Kunal Bahl, co-founder of Snapdeal and Titan Capital. A cold email led to a role at Titan Capital, where Chauhan worked on investment research across fintech, healthtech, and consumer brands.

At Titan Capital, he studied founder behaviour, unit economics, and market structure. He saw why many startups fail and what helps some scale. This experience shaped how he later built Zivov, with a focus on cost control and clear outcomes.

By 2021, Chauhan decided to step away from investing and work full time on his own company.

Personal reason behind Zivov

Zivov was co-founded by Aryan Chauhan and his mother. The idea came from personal loss. Chauhan lost both his grandparents to diabetes. He saw how hard long-term care can be and how expensive monitoring tools remain for many families.

India has one of the highest diabetes populations in the world. Many patients rely on medication without enough support on diet, activity, or mental health. Chauhan believed a structured, tech-led approach could help improve outcomes.

Zivov began as a chronic care platform. It offered diabetes remission plans that combined nutrition guidance, fitness routines, and mental health support. The goal was to help users reduce HbA1c levels to safer ranges within six months.

The platform scaled to more than 70,000 users in its early phase.

Adding glucose monitoring to the model

In 2023, Aryan Chauhan expanded Zivov’s offering by adding continuous glucose monitoring. CGMs track blood sugar levels throughout the day and send readings to a phone. This data helps users see how food, sleep, and activity affect glucose levels.

In India, Abbott controls most of the CGM market. These devices work well but cost more than many patients can afford.

Zivov built its own software layer that scans data from Abbott CGM sensors. This allows Zivov to offer CGM-based care at less than half the cost charged by many providers. The lower price has helped widen access to glucose monitoring.

The system uses CGM data to adjust food and lifestyle plans in near real time. This helps users understand patterns rather than rely on fixed advice.

How Zivov differs from other apps

Many diabetes apps focus on logging meals or reminding users to take medicine. Zivov takes a different route. It links real glucose data with action. Plans change based on how a user’s body responds.

Aryan Chauhan says the focus is remission, not short-term control. Zivov defines remission as stable glucose levels without adding medication over time. The company tracks outcomes through data rather than self-reported habits.

This approach places Zivov between medical devices and lifestyle care, a space that remains underdeveloped in India.

Industry response and recognition

Kunal Bahl has described Aryan Chauhan as a founder who combines product depth with execution focus. He has said Chauhan learns fast and stays close to the problem he wants to solve.

Aryan Chauhan and Zivov were featured in Forbes India’s 30 Under 30 list, which brought wider attention to the startup’s work in diabetes care.

Latest plans and next phase

As of 2025, Zivov is preparing its next phase of growth. The company plans to develop its own continuous glucose monitoring devices. This would reduce reliance on third-party hardware and lower costs further.

Zivov is also exploring international markets with high diabetes rates and limited access to affordable monitoring tools. Expansion will focus on regions where cost remains the main barrier.

Chauhan says the aim is scale with control. The company plans to grow user numbers without losing accuracy or personalisation.

Why Aryan Chauhan’s journey matters

At 22, Aryan Chauhan is working in a sector that most young founders avoid due to complexity. Healthcare requires patience, data accuracy, and trust. His path shows how early exposure, clear learning, and personal motivation can shape solutions for large problems.

The Aryan Chauhan Zivov story reflects a wider shift in Indian healthtech. Startups now focus less on surface features and more on outcomes and cost reduction. As diabetes cases continue to rise, such models may shape how care reaches more people.

FAQs

Q1. Who is Aryan Chauhan?
Aryan Chauhan is an Indian entrepreneur and the co-founder of Zivov, a healthtech startup focused on diabetes remission and glucose monitoring.

Q2. What is Aryan Chauhan’s age?
He is 22 years old.

Q3. What is Zivov?
Zivov is a healthtech startup that offers personalised diabetes remission plans and affordable continuous glucose monitoring support.

Q4. Where does Aryan Chauhan study?
He studies in the Jerome Fisher Program in Management and Technology at the University of Pennsylvania and is currently on academic leave.